Takeda registers Phase 3b trial of zasocitinib for palmoplantar psoriasis
Takeda posted a new Phase 3b study of oral zasocitinib in moderate-to-severe non-pustular palmoplantar psoriasis, not yet recruiting.
Takeda's clinical trial registry activity for the week centers on a single new listing.
- Takeda registered a Phase 3b, open-label study (NCT07752108) testing zasocitinib, also known as TAK-279 or NDI-034858, as an oral tablet1 in adults with moderate-to-severe non-pustular palmoplantar psoriasis. The study is not yet recruiting, with an estimated start date of November 1, 20261, and plans to enroll 40 participants1. The primary outcome measures the percentage of participants achieving a Palmoplantar Investigator's Global Assessment score of 0 or 1, with at least a 2-point reduction from baseline, at Week 161.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.